Derek Grose1, David S Morrison2, Graham Devereux3, Richard Jones1, Dave Sharma4, Colin Selby5, Kirsty Docherty4, David McIntosh1, Greig Louden6, Marianne Nicolson7, Donald C McMillan8, Robert Milroy9. 1. Department of Clinical Oncology, Beatson Oncology Centre, Glasgow, UK. 2. Department Public Health, University of Glasgow, Glasgow, UK. 3. Department of Child Health, University of Aberdeen, Aberdeen, UK. 4. Department of Respiratory Medicine, Inverclyde Royal Hospital, Inverclyde, UK. 5. Department of Respiratory Medicine, Queen Margaret Hospital, Dunfermline, UK. 6. Department of Internal Medicine, Wishaw General Hospital, Wishaw, UK. 7. Department of Oncology, Aberdeen Royal Infirmary, Aberdeen, UK. 8. Department of Surgery, University of Glasgow, Glasgow, UK. 9. Glasgow Royal Infirmary, Glasgow, UK.
Abstract
BACKGROUND: Survival from lung cancer remains poor in Scotland, UK. Although the presence of comorbidities is known to influence outcomes, detailed quantification of comorbidities is not available in routinely collected audit or cancer registry data. The aim of the present study was to assess the prevalence and severity of comorbidities in patients with newly diagnosed lung cancer across four centres throughout Scotland using validated criteria. METHODS: Between 2005 and 2008, all patients with newly diagnosed lung cancer coming through the multidisciplinary teams in four Scottish centres were included in the study. Patient demographics, WHO/Eastern Cooperative Oncology Group performance status, clinicopathological features and primary treatment modality were recorded. RESULTS: Details of 882 patients were collected prospectively. The majority of patients (87.3%) had at least one comorbidity, the most common being weight loss (53%), chronic obstructive pulmonary disease (43%), renal impairment (28%) and ischaemic heart disease (27%). A composite score was produced that included both number and severity of comorbidities. One in seven patients (15.3%) had severe comorbidity scores. There were statistically significant variations in comorbidity scores between treatment centres and between non-small cell lung carcinoma treatment groups. Disease stage was not associated with comorbidity score. CONCLUSIONS: There is a high prevalence of multiple, severe comorbidities in Scottish patients with lung cancer, and these vary by site and treatment group. Further research is needed to determine the relationship between comorbidity scores and survival in these patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Survival from lung cancer remains poor in Scotland, UK. Although the presence of comorbidities is known to influence outcomes, detailed quantification of comorbidities is not available in routinely collected audit or cancer registry data. The aim of the present study was to assess the prevalence and severity of comorbidities in patients with newly diagnosed lung cancer across four centres throughout Scotland using validated criteria. METHODS: Between 2005 and 2008, all patients with newly diagnosed lung cancer coming through the multidisciplinary teams in four Scottish centres were included in the study. Patient demographics, WHO/Eastern Cooperative Oncology Group performance status, clinicopathological features and primary treatment modality were recorded. RESULTS: Details of 882 patients were collected prospectively. The majority of patients (87.3%) had at least one comorbidity, the most common being weight loss (53%), chronic obstructive pulmonary disease (43%), renal impairment (28%) and ischaemic heart disease (27%). A composite score was produced that included both number and severity of comorbidities. One in seven patients (15.3%) had severe comorbidity scores. There were statistically significant variations in comorbidity scores between treatment centres and between non-small cell lung carcinoma treatment groups. Disease stage was not associated with comorbidity score. CONCLUSIONS: There is a high prevalence of multiple, severe comorbidities in Scottish patients with lung cancer, and these vary by site and treatment group. Further research is needed to determine the relationship between comorbidity scores and survival in these patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Jasmin Bossert; Marion Ludwig; Pamela Wronski; Jan Koetsenruijter; Katja Krug; Matthias Villalobos; Josephine Jacob; Jochen Walker; Michael Thomas; Michel Wensing Journal: NPJ Prim Care Respir Med Date: 2021-01-28 Impact factor: 2.871